New ways to treat tumors with KEAP1 mutations
Novel approaches to target KEAP1 mutant tumors
This study is looking at new ways to treat lung cancer with KEAP1 gene mutations, which can make the cancer tougher to beat, by exploring how these mutations change how cancer cells use energy and testing new treatments that could help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11067843 on NIH RePORTER |
What this research studies
This research investigates innovative methods to target lung adenocarcinoma tumors that have mutations in the KEAP1 gene, which are known to make the cancer more aggressive and resistant to standard treatments. The team will explore how these mutations affect cancer cell metabolism and test new therapies that could specifically disrupt these altered metabolic pathways. By using both genetic and drug-based approaches in laboratory models, the research aims to identify effective treatment combinations that could improve outcomes for patients with these challenging tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with KRAS mutant lung adenocarcinoma who also have KEAP1 mutations.
Not a fit: Patients without KRAS mutations or those with other types of lung cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with KEAP1 mutant lung adenocarcinoma.
How similar studies have performed: Previous research has shown promise in targeting metabolic pathways in cancer, suggesting that this approach could yield significant advancements.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Papagiannakopoulos, Thales — New York University School of Medicine
- Study coordinator: Papagiannakopoulos, Thales
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.